Cerluten
- Category
- Bioregulators
- Administration routes
- Oral
- Regulatory status
- Not FDA-approved
A bioregulator peptide complex from bovine brain tissue, marketed to support cognition and slow age-related brain decline via effects on neuron gene expression. Human evidence is minimal, cognitive and metabolic benefit claims are speculative, and the neuroprotective signal is low-confidence, mostly animal-derived. Most supply is unregulated research-grade product of uncertain purity, plus an unresolved prion concern given its origin. Not FDA-approved.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Cerluten is a natural peptide bioregulator derived from the brain tissues of young calves (no older than 12 months of age). Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it belongs to the Cytomaxes class of peptide bioregulators -- organ-specific peptide complexes designed to restore and maintain the function of targeted tissues. Cerluten specifically targets the central nervous system, where it is believed to normalize metabolic processes in brain cells and support neuroprotective pathways.
The underlying theory is that short-chain peptides interact with specific DNA sequences to regulate gene expression and protein synthesis in an organ-specific manner. In the case of Cerluten, these peptides are thought to support neuronal health, promote cognitive function, and protect against age-related neurodegenerative changes. It is part of a broader family of Khavinson bioregulators that have been used in Russia for decades, initially developed for the Soviet military to protect troops from various environmental stressors.
Cerluten is sold as a dietary supplement in capsule form (0.2g per capsule, typically in packs of 20 or 60). It is not approved as a drug by any Western regulatory authority. While neuroprotective properties have been described in Russian clinical literature, independent Western clinical trials are absent, and the evidence base consists primarily of small Russian studies and preclinical work.
How it works in the body
A brain-derived peptide complex with proposed effects on gene regulation. The cited reviews do not establish a Cerluten-specific neuronal mechanism.
Research overview
Cerluten has been studied primarily at the St. Petersburg Institute of Bioregulation and Gerontology. The research context includes a broader body of work by Khavinson et al. on peptide bioregulators and their interaction with DNA. A PubMed-indexed review (PMID 24738258) compares neuroprotective peptide groups including polypeptide complexes (cortexin, cerebrolizin) and short peptides (semax, kortagen, pinealon), describing their clinical application in elderly patients and molecular mechanisms of neuroprotection. Cerluten is part of the Cytomaxes class and is positioned as a natural complex complementary to synthetic short peptides like Pinealon. The Institute's own clinical reports describe improvements in cognitive function and reduction of neurological symptoms in elderly patients receiving Cerluten as part of multi-bioregulator protocols. However, there are no registered Western clinical trials and no independent replication of Russian findings.
Who researches Cerluten?
Commonly researched by
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People researching support for cognitive function in elderly patients
One of the primary studied benefits of Cerluten.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(3)
Rated by level of concern
Allergic reaction to animal-derived peptides
LowPMID 36324709 (safety outcomes; Cerebrolysin RR 0.96, 95%CI 0.78-1.18); Cortexin product labeling (hypersensitivity contraindication)
Prion disease concerns (bovine brain origin)
TheoreticalEMA Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products, EMEA/410/01 rev.3 (https://www.ema.europa.eu/en/minimising-risk-transmitting-animal-spongiform-encephalopathy-agents-human-veterinary-medicinal-products-scientific-guideline)
Lack of independent quality control
HighFDA DSHEA/dietary supplement regulatory framework (https://www.fda.gov/food/dietary-supplements); no PubMed records for Cerluten; no ClinicalTrials.gov registration found
Interaction summary(7)
Rated by direction with this peptide
Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine
CautionTheoreticalNo co-administration study exists and no additive benefit has been demonstrated, so the only defensible entry here is a substitution caution: Cerluten must never replace or delay a prescribed dementia therapy, and any perceived benefit that prompts a patient to reduce standard treatment is the real hazard. Mechanistic non-overlap is often cited to argue for additive effect, but that argument rests on unverified assumptions about Cerluten's activity.
No co-administration data in PubMed for Cerluten; class efficacy background PMID 36324709
Other animal-derived neuropeptide preparations (Cerebrolysin, Cortexin, Actovegin)
CautionTheoreticalUsing more than one heterologous brain-tissue extract multiplies antigenic and TSE-sourcing exposure without any evidence of added benefit; the systematic review covering exactly this class (Cerebrolysin, Actovegin, Cortexin) rated certainty of evidence low to very low with moderate-to-high risk of bias. No study has examined combined use.
PMID 36324709 (Alsulaimani & Quinn, systematic review of this drug class)
Antiepileptic drugs / patients with a seizure disorder
CautionTheoreticalNeurotrophic peptide preparations in this class carry labeling cautions in grand mal epilepsy because of a possible effect on seizure threshold; Cerluten has no seizure-threshold data of its own and no case reports, so this is class-label extrapolation from injectable products to an oral supplement rather than a documented interaction. Clinical monitoring rather than assumed safety.
Cerebrolysin product labeling caution in grand mal epilepsy (class labeling); no Cerluten-specific data in PubMed
Immunosuppressants and biologic immunomodulators (in transplant or autoimmune patients)
CautionTheoreticalAn undisclosed heterologous animal-protein preparation is a poorly characterized antigenic input in patients whose immune status is being deliberately controlled. This is inference from the product's undisclosed composition, not an observed interaction — no immunogenicity or pharmacokinetic data exist for Cerluten.
Inference from undisclosed composition; no published immunogenicity or PK data for Cerluten
CNS depressants (benzodiazepines, opioids, alcohol, sedating antihistamines)
NeutralTheoreticalNo pharmacokinetic or pharmacodynamic interaction has been reported or is mechanistically predicted — orally administered peptide complexes are not known CYP substrates or inhibitors — so this pairing is listed to record the absence of a signal, not a hazard. Absence of reports partly reflects absence of any surveillance.
No interaction reports located in PubMed or FDA labeling for this class
Pregnancy, breastfeeding, and pediatric use
CautionModerateNot a drug interaction but a population contraindication: peptide bioregulators of this class are contraindicated in pregnancy and lactation by their own manufacturers, and no reproductive-toxicology or pediatric safety data have been published for Cerluten. Severity reflects the actionable avoid-in-pregnancy recommendation, not any demonstrated fetal harm.
Manufacturer labeling for Khavinson peptide bioregulators (pregnancy/lactation contraindication); no reproductive toxicology in PubMed
Warfarin and other narrow-therapeutic-index drugs
NeutralTheoreticalNo documented interaction exists and none is mechanistically predicted. The only concern is generic to unassayed supplements: composition is unverified, so unlabeled excipients or contaminants cannot be excluded — a general argument for INR monitoring when adding any unregulated product, not a Cerluten-specific mechanism.
FDA dietary supplement regulatory framework (https://www.fda.gov/food/dietary-supplements); no Cerluten-specific interaction reports
Known risks(3)
Allergic reaction to animal-derived peptides
LowAs a product derived from bovine brain tissue, there is a theoretical risk of allergic reaction in sensitive individuals. No serious adverse events have been reported in available literature.
Prion disease concerns (bovine brain origin)
TheoreticalProducts derived from bovine brain tissue carry a theoretical risk related to prion diseases (BSE/mad cow disease). Manufacturers state that source animals are from certified BSE-free herds and materials undergo extensive processing.
Lack of independent quality control
ModerateDietary supplements remain subject to FDA regulation. Product quality and consistency may vary; supplement marketing does not establish drug approval. No independent third-party testing data is publicly available.
Drug interactions(2)
CNS-active medications (antidepressants, anxiolytics, antipsychotics)
Theoretical interaction due to shared CNS targets; no documented interactions but caution advised
Anticoagulants
No known interaction; monitor as with any new supplement
Research & benefits
Evidence base
- Evidence Level
- Very Limited Evidence
- Total Studies
- 5
- Human Studies
- 100
Clinical evidence for Cerluten consists primarily of small open-label studies conducted at the St. Petersburg Institute of Bioregulation and Gerontology. These studies report improvements in cognitive function, memory, and neurological symptoms in elderly patients, but lack randomization, blinding, and placebo controls. No independent Western clinical trials have been conducted. The neuroprotective peptide review (PMID 24738258) provides context on the broader class but does not constitute direct evidence for Cerluten specifically.
Researched for(3)
Rated by confidence in the evidence
Support for cognitive function in elderly patients
SpeculativeA developer clinical report exists; independent confirmation is lacking.
PMID 36324709 (Cereb Circ Cogn Behav 2021; Cortexin = 1 trial, n=80, certainty low to very low); PMID 29652302 (Zh Nevrol Psikhiatr 2018; open-label multicenter, n=635 children); PubMed search for 'Cerluten' = 0 results (https://pubmed.ncbi.nlm.nih.gov/?term=Cerluten)
Neuroprotective activity in age-related CNS decline
LowExtensive animal data support the peptide class, but no direct testing of Cerluten itself.
PMC12024793 — 'Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental Delay', Biomedicines 2025 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12024793/); PMID 27383168 (Bull Exp Biol Med 2016, aged-rat cortex microvasculature); PMID 24738258 (Adv Gerontol 2013 review)
Normalization of brain cell metabolism
SpeculativeMechanism-based only; cited studies used a different peptide in cell cultures, not Cerluten in humans.
PMID 32019204 (Molecules 2020; Epitalon in hGMSCs, histone binding by molecular modelling); PMID 35457077 (Int J Mol Sci 2022, review)
Benefits(3)
Support for cognitive function in elderly patients
Khavinson Institute clinical reports; review PMID 24738258
Neuroprotective activity in age-related CNS decline
Russian clinical literature; Khavinson et al. bioregulator research program
Normalization of brain cell metabolism
Preclinical data from St. Petersburg Institute of Bioregulation and Gerontology
Key studies(2)
Umnov RS, Lin'kova NS, Khavinson VKh
Advances in Gerontology
2013
Comparative review of neuroprotective peptide groups including polypeptide complexes and short peptides, describing clinical application in elderly patients and molecular mechanisms of neuroprotective activity.
Peptide bioregulation of aging: results and prospects
ReviewN/A (review)Anisimov VN, Khavinson VKh
Biogerontology
2010
Comprehensive review of 35 years of peptide bioregulator research showing that organ-specific peptides can restore physiological functions and reduce mortality in aging populations over 6-12 year follow-up periods.
Regulation & availability
Why researchers look at it
Cerluten targets brain cell metabolism through organ-specific peptides derived from young animal brain tissue. It is part of the Khavinson bioregulator system used for decades in Russian anti-aging medicine, though Western clinical evidence remains limited.
- Estimated cost
- $30-60/mo (capsules)
- FDA status
- Not FDA-approved; not reviewed by FDA; sold as dietary supplement internationally
- WADA status
- Not individually named in the 2026 List. S0 prohibits at all times pharmacological substances not covered by later sections that lack current approval by any governmental health authority for human therapeutic use. Cerluten's substance-specific anti-doping status requires confirmation.
- Prescribability
- Available in Russia as dietary supplement; not approved in USA/EU
- Availability
- Sold as a dietary supplement in Russia. Not available through conventional pharmacies or medical channels in the USA or EU.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(2)
- 1990sDeveloped at St. Petersburg Institute of Bioregulation and Gerontology by Khavinson team
- 2000sCommercialized as dietary supplement (Cytomaxes class) in Russia
Sources & FAQs
Research sources(3)
Frequently asked questions(2)
What is Cerluten made from?
Cerluten contains a complex of low-molecular-weight peptides (under 5,000 Da) extracted from the brain tissue of young calves aged up to 12 months. These peptides are processed through pharmaceutical-grade filtration methods.
Is there strong clinical evidence for Cerluten?
No. Evidence is limited to small Russian clinical studies without Western-standard randomization or blinding. No independent clinical trials have been conducted outside Russia. The peptide is classified as a dietary supplement, not a drug.